Group 1: Federal Reserve and Employment Data - Goldman Sachs expects the Federal Reserve to maintain its current policy in January, with two rate cuts anticipated in the remainder of 2026 due to initial signs of labor market stability [1] - JPMorgan has removed its forecast for a rate cut in 2026, now predicting a 25 basis point increase in Q3 2027 [1] - Societe Generale believes the decline in unemployment and rising wages provide a stronger rationale for the Fed to hold rates steady in January [1] Group 2: Oil Prices and Geopolitical Risks - Goldman Sachs indicates that despite ongoing geopolitical risks, oil prices may continue to decline due to ample supply, predicting Brent and WTI crude oil prices to average $56 and $52 per barrel respectively in 2026 [2] Group 3: Chinese Economic Outlook - CITIC Securities forecasts a "mild re-inflation" in China in 2026, driven by a slight increase in PPI and CPI, with core CPI expected to rise due to various factors including food prices and service costs [3] - CITIC Securities also notes that the balance between external and internal demand will be crucial for the A-share market, with a higher probability of upward movement in early 2026 [4] Group 4: Commodity Prices and Market Trends - CITIC Jinpu predicts that copper prices will continue to rise, with the market not yet at an end, and expects significant support for copper prices despite short-term corrections [5] - CITIC Securities anticipates that investment in the power grid during the 14th Five-Year Plan period may reach 3.8 trillion yuan, focusing on high-quality development and stability in the energy sector [6] Group 5: Currency and Market Dynamics - Huatai Securities expects the Federal Reserve to pause rate cuts from January to May, with potential cuts occurring after the new Fed chair takes office [7] - Huachuang Securities highlights the commercialization of brain-computer interfaces, indicating a growing market with significant potential for expansion beyond the medical field [8] - Shenwan Hongyuan predicts that the RMB will appreciate by 2-3% annually over the next few years, with a total appreciation of over 30% in the next decade, benefiting the stock market [10]

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry as of January 11, 2026 [3] Core Insights - 2025 marked a significant year for Chinese innovative drugs going overseas, with total transaction amounts reaching $135.655 billion, including $7 billion in upfront payments and 157 deals, setting historical highs [4] - The innovative drug index saw a 35.31% increase in 2025, outperforming the CSI 300 index by 17.65% [4] - The trend of Chinese innovative drugs going global is expected to strengthen in 2026, with significant deals such as the one between Yilian Biotech and Roche for the YL201 project, which includes a $570 million upfront payment [4] - The small nucleic acid drug sector is experiencing breakthroughs, with GSK's Bepirovirsen showing positive results in Phase III trials for chronic hepatitis B, potentially becoming the first drug to achieve functional cure [5] - The report highlights the importance of oral autoimmune drugs, with Takeda's TYK2 inhibitor showing promising results in treating moderate to severe plaque psoriasis [6] - The brain-computer interface technology is entering a critical industrialization phase, with companies like Neuralink set to produce devices in 2026, supported by favorable policies and clinical trials in China [8] - The ZAP-X radiotherapy device is expected to capture a significant market opportunity in China, with the non-invasive tumor radiotherapy market projected to grow from RMB 27.2 billion in 2018 to RMB 59.4 billion by 2024 [10] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry index underperformed the CSI 300 index by 2.13% over the past week, ranking 25th among 31 industry indices [28] - Over the past month, the pharmaceutical industry index also lagged behind the CSI 300 by 5.42%, ranking 27th [29] 2. Pharmaceutical Sector Trends and Valuation - The current PE (TTM) for the pharmaceutical industry index is 36.95, above the five-year historical average of 31.12 [52] 3. Recent Research Achievements - The report includes various deep-dive studies on topics such as the growth of biological agents and oral drugs, and the impact of policy support on the inhalation drug industry [55] 4. Important Industry Policies and News - Recent policies include the issuance of the fourth batch of encouraged generic drug directories by the National Medical Products Administration [57] - Significant news includes GSK's announcement of positive Phase III results for Bepirovirsen and Yilian Biotech's licensing agreement with Roche [58][59]

Report Summary 1. Report Industry Investment Rating - Not provided. 2. Core View - The report focuses on the tin market, showing that long - position funds faced obstacles, leading to a price increase followed by a decline [1]. 3. Summary by Relevant Catalogs 3.1 Fundamental Tracking - **Futures and Spot Electronic Disk Data**: - The closing price of the Shanghai Tin main contract was 359,050 with a daily increase of 2.93%, and the night - session closing price was 355,170 with a - 0.28% change compared to the previous day. The closing price of the LME Tin 3M electronic disk was 44,650 with a 0.34% increase [1]. - The trading volume of the Shanghai Tin main contract was 459,909, an increase of 134,924 from the previous day, and the position was 43,969, an increase of 2,774. The trading volume of the LME Tin 3M electronic disk was 180, a decrease of 9, and the position was 13,988, an increase of 53 [1]. - The inventory of Shanghai Tin was 6,780, a decrease of 306, and the inventory of LME Tin was 5,405, a decrease of 15. The cancellation warrant ratio of LME Tin was 6.57%, a decrease of 0.38% [1]. - **Spot and Price Difference Data**: - The price of SMM 1 tin ingot was 355,950, an increase of 14,900 from the previous day; the average price of Yangtze River Non - ferrous 1 tin was 357,300, an increase of 15,200 [1]. - The LME Tin (spot/three - month) spread was - 65, a decrease of 35; the spread between the near - month contract and the first - continuous contract was 162,370, unchanged; the spread between the spot and the futures main contract was 8,480, an increase of 750 [1]. - **Industry Chain Key Price Data**: - The price of 40% tin concentrate in Yunnan was 343,950, an increase of 14,900; the price of 60% tin concentrate in Guangxi was 347,950, an increase of 14,900 [1]. - The price of 63A solder bar was 237,250, an increase of 9,500; the price of 60A solder bar was 227,250, an increase of 9,000 [1]. 3.2 Macro and Industry News - The memory market has entered a "super bull market" with a 40% - 50% increase expected in Q1 [2]. - Eight departments including the Ministry of Industry and Information Technology aim to accelerate the industrialization and commercialization of new terminals such as AR/VR wearable devices and brain - computer interfaces [2]. - The People's Bank of China carried out 110 billion yuan of outright reverse repurchase operations on January 8 [2]. - The US will "distribute on commission" Venezuelan oil and requires Venezuela to cut economic ties with China and Russia [2]. 3.3 Trend Intensity - The tin trend intensity is 0, indicating a neutral trend. The range of trend intensity is [- 2,2], with - 2 representing the most bearish and 2 representing the most bullish [2][3]